Letermovir Prophylaxis Guided by Cytomegalovirus Cell-Mediated Immunity Improves the Outcomes of Allogeneic Hematopoietic Stem Cell Transplant Recipients
Clinical Infectious Diseases · 2026
DOI: 10.1093/cid/ciaf410 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Infectious Diseases, 2026. Verfasst von Luxiang Wang und 14 weiteren Autor:innen. Beteiligte Einrichtung: Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine at Shanghai, Ruijin H…. Hauptthemen laut MEDLINE: Cytomegalovirus Infections, Hematopoietic Stem Cell Transplantation, Antiviral Agents, Cytomegalovirus. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 29 Literaturangaben.
Abstract (Originalsprache)
Background
The control of cytomegalovirus (CMV) reactivation after allogeneic hematopoietic stem cell transplantation (allo-HSCT) depends heavily on the reconstitution of CMV-specific cell-mediated immunity (CMV-CMI). This study aimed to assess whether CMV-CMI–guided letermovir prophylaxis is more effective than a fixed-duration approach in reducing the incidence of late-onset clinically significant CMV infection (cs-CMVi).
Methods
This retrospective study included 182 adults who underwent allo-HSCT at 4 participating hospitals. Individuals who received transplantation between June 2022 and April 2023 were treated with a fixed 100-day course of letermovir (fixed-duration group, n = 78), while those receiving transplantation from February 2023 to February 2024 received letermovir based on their CMV-CMI status (CMV-CMI–guided group, n = 104).
Results
The 1-year cumulative incidence of late-onset cs-CMVi was significantly lower in the CMV-CMI–guided group compared with the fixed-duration group (9.7% vs 24.8%, P = .019). The CMV-CMI–guided group also had improved overall survival (89.1% vs 77.1%, P = .04) and relapse-free survival (88.4% vs 76.8%, P = .01). Patients were divided into high-risk (n = 36) and low-risk (n = 146) groups, based on risk factors for late-onset cs-CMVi. Among high-risk individuals, the cumulative incidence of late-onset cs-CMVi was significantly lower in the CMV-CMI–guided group than in the fixed-duration group (12.5% vs 46.3%, P = .04).
Conclusions
CMV-CMI–guided letermovir prophylaxis may help reduce the risk of late-onset cs-CMVi, particularly in individuals at high risk. Clinical Trials Registration NCT06708130.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine at Shanghai, Ruijin Hospital affiliated to Shanghai Jiao Tong University School of Medicine…
- Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
- Department of Hematology, Lanzhou University Second Hospital, Lanzhou, China.
- Department of Hematology, Shanghai Liquan Hospital, Shanghai, China.
- Department of Hematology, Shanghai Zhaxin Hospital, Shanghai, China.
- Department of Health Statistics, Naval Medical University, Shanghai, China.
ORCID-Profile: Yang Cao, Xiaoxia Hu
Zitieren
APA
Wang, L., Huang, J., Jiang, C., Huang, M., Guo, X., Li, S., Zhang, Z., Huang, J., Lu, H., Pan, Z., Zhu, J., Chen, Q., He, Y., Cao, Y., & Hu, X. (2026). Letermovir Prophylaxis Guided by Cytomegalovirus Cell-Mediated Immunity Improves the Outcomes of Allogeneic Hematopoietic Stem Cell Transplant Recipients. Clinical Infectious Diseases. https://doi.org/10.1093/cid/ciaf410
Vancouver
Wang L, Huang J, Jiang C, Huang M, Guo X, Li S, et al. Letermovir Prophylaxis Guided by Cytomegalovirus Cell-Mediated Immunity Improves the Outcomes of Allogeneic Hematopoietic Stem Cell Transplant Recipients. Clinical Infectious Diseases. 2026. doi:10.1093/cid/ciaf410
BibTeX
@article{Wang2026,
author = {Wang, Luxiang and Huang, Jingtao and Jiang, Chuanhe and Huang, Meijuan and Guo, Xiaojia and Li, Su and Zhang, Zilu and Huang, Jiayu and Lu, Haiyang and Pan, Zengkai and Zhu, Jun and Chen, Qi and He, Yang and Cao, Yang and Hu, Xiaoxia},
title = {Letermovir Prophylaxis Guided by Cytomegalovirus Cell-Mediated Immunity Improves the Outcomes of Allogeneic Hematopoietic Stem Cell Transplant Recipients},
journal = {Clinical Infectious Diseases},
year = {2026},
doi = {10.1093/cid/ciaf410}
}
EUVIMED